Trial NCT05289037
Publication Branche A, Clin. Infect. Dis., 2023
Primary outcome on the report: Evaluate the magnitude and breadth of SARS-CoV-2 specific antibody titers in serum samples by estimating 95% confidence intervals (CI) for the geometric mean titer (GMT) at each timepoint when samples are collected.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.